middle.news
How Will Clarity’s $203M Raise Propel Its Cancer Drug Trials?
9:50am on Monday 28th of July, 2025 AEST
•
Healthcare
Read Story
How Will Clarity’s $203M Raise Propel Its Cancer Drug Trials?
9:50am on Monday 28th of July, 2025 AEST
Key Points
Raised $203 million via institutional placement at $4.20 per share
Placement price represents a premium to recent trading levels
Pro-forma cash balance of approximately $288 million post-raise
Funds earmarked for Phase 3 clinical trials and NDA planning
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Clarity Pharmaceuticals (ASX:CU6)
OPEN ARTICLE